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Abstract: Liver regeneration restores the original functionality of hepatocytes and 
cholangiocytes in response to injury. It is regulated on several levels, with different cellular 
populations contributing to this process, eg, hepatocytes, liver precursor cells, intrahepatic stem 
cells. In response to injury, mature hepatocytes have the capability to proliferate and give rise to 
new hepatocytes and cholangiocytes. Meanwhile, liver precursor cells (oval cells) have become 
the most recognized bipotential precursor cells in the damaged liver. They rapidly proliferate, 
change their cellular composition, and differentiate into hepatocytes and cholangiocytes to 
compensate for the cellular loss and maintain liver homeostasis. There is a growing body of 
evidence that oval cells originate from the intrahepatic stem cell(s), which in turn give(s) rise 
to epithelial, including oval cells, and/or other hepatic cells of nonepithelial origin. Since there 
is a close relationship between the liver and hematopoiesis, bone marrow derived cells can also 
contribute to liver regeneration by the fusion of myeloid cells with damaged hepatocytes, or 
differentiation of mesenchymal stem cells into hepatocyte-like cells. The current review discusses 
the contribution of different cells to liver regeneration and their characteristics.
Keywords: hepatic progenitor, liver disease, liver precursor cells, oval cells, hepatocytes, 
intrahepatic stem cells, cholangiocytes
Cells contributing to liver regeneration
It is believed that the ancient myth of Prometheus describes the capability of the liver 
to restore its mass. Punished by Zeus for the theft of fire, Prometheus, a Titan, was 
chained for eternity to a rock in the Caucasus; each day an eagle would eat his liver and 
each night the liver would regenerate only for the eagle to return the following day.
Liver regulates different functions during growth, development and adulthood. 
It serves as the first site of embryonic hematopoiesis, but turns into a vital detoxifying 
system in the postnatal period. In addition, liver serves as a major storage of glycogen 
and vitamin A, and remains the only organ in the adult organism capable of self renewal.1 
Liver regeneration is a rapid and tightly orchestrated process that efficiently and precisely 
restores the original cellular mass and functionality of hepatocytes and cholangiocytes. 
It is regulated on several levels, with different cellular populations contributing to liver 
regeneration. First, mature hepatocytes (in contrast to mature hematopoietic cells) possess 
the ability to proliferate and repopulate the damaged liver (Figure 1). Some studies sug-
gest that hepatocytes can give rise not only to new hepatocytes, but can also differentiate 
into cholangiocytes, suggesting that hepatocytes are bipotential cells, which possess stem 
cell-like features. Second, liver precursor cells (oval cells) differ from other cells in the 
liver by their ability to extensively proliferate, migrate in a specific zone (lobule) and 
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differentiate into hepatocytes and cholangiocytes. The concept 
of “liver precursor cells” has not been widely accepted until 
the last decade, most likely due to the established and recognized 
regenerative potential of hepatocytes. A population of small 
portal cells with ovoid nuclei and high nuclear/cytoplasmic 
ratio, named oval cells, was first identified in 1978 by Shino-
zuka and colleagues2,3 Since then, oval cells have become the 
most recognized precursor cells in the liver. The term “oval 
cells” is widely used to characterize a heterogeneous popula-
tion of bipotential transient amplifying cells originating in the 
Canal of Hering, and activated in the liver as a result of injury 
or insult.4–6 The number of quiescent (or dormant) oval cells 
is very low under physiological conditions, but in response 
to an abruptly changing microenvironment, oval cells rapidly 
proliferate, change their morphology, surface markers and 
cellular composition, and differentiate to compensate for 
the cellular loss to maintain liver homeostasis.7 Third, since 
oval cells represent a mixed precursor population, they most 
likely differentiate from the “hypothetical true” intrahepatic 
stem cell(s).5,8,9 Here we call the intrahepatic stem cell hypo-
thetical because it has not been well defined, but the growing 
evidence suggests its existence. Hypothetical intrahepatic stem 
cell(s) can, therefore, give rise to oval cells, causing their het-
erogeneity and/or other hepatic cells of non-epithelial origin.9 
Fourth, since there is a close relationship between the liver 
and hematopoiesis, the contribution of bone marrow (BM) 
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Figure 1 Cells contributing to liver regeneration.
Notes: Different cellular types regulate liver regeneration on several levels. Contribution of mature hepatocytes to regeneration of hepatic parenchymal cells is shown in black. 
Liver precursor cells with bipotential differentiation capacity are shown in red. Proposed pathways of liver regeneration, which require further clarification, are shown in grey.
Abbreviations: HSC, hepatic stem cells; MSC, mesenchymal stem cells.
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derived cells to liver regeneration has to be considered. Early 
studies proposed that hematopoetic cells can contribute to the 
replenishment of hepatic stem cells and oval cells.10,11 However, 
under most circumstances, reconstitution of the liver with BM 
cells results from fusion of damaged hepatocytes with myeloid 
cells.12 Furthermore, mesenchymal stem cells derived from the 
bone marrow or adipose tissues have a capacity to improve liver 
function, perhaps by giving rise to hepatocyte-like cells.13,14 
Thus, we cannot exclude that circulating (hematopoietic and/or 
mesenchymal) stem cells cannot ameliorate the intrahepatic 
stem cells in response to severe injury.
Hepatocytes
In normal adult liver, mature hepatocytes exhibit quiescent 
phenotype, stay in the G0 phase of the cell cycle, and show 
minimal turnover. However, upon hepatocyte loss (such 
as shock liver, liver infection or surgical resection), these 
mature hepatocytes undergo cell division, while maintain-
ing their metabolic function.15–18 The most widely used 
model to study hepatocyte transplantation, proliferation and 
reconstitution potential is the fumaryl-aceto-acetate hydro-
lase (FAH) knockout mice, in which the metabolic disorder 
causes extensive, continuous liver injury. In this murine 
model for the human disease, hereditary tyrosinemia type 1, 
donor hepatocytes expressing the FAH protein have a strong 
selective growth advantage over the recipient hepatocytes.12,19 
Hepatocyte repopulation in wild type mice or FAH-/- mice is 
very rare. However, high efficiency of hepatocyte repopula-
tion in FAH-/- mice is achieved only through massive selec-
tion pressure, caused by withdrawal of the protective drug 
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione 
(NTBC) from drinking water, which results in severe loss 
of hepatocytes. Therefore the normal lobular structure and 
liver functions of FAH-/- mice can be totally restored by 
transplantation of wild type hepatocytes.18,19 This model has 
demonstrated that normal adult hepatocytes can be serially 
transplanted through seven generations of mice, and that 
single hepatocytes can be clonally amplified like stem cells, 
and serially passaged to repopulate the FAH-/- mouse liver.20 
As liver reconstituting cells, mature hepatocytes have the 
capacity to reconstitute almost 70% of livers in FAH-/- mice.20 
Successful transplantation of hepatocytes in mice encourage 
generation of “humanized” mouse models of liver disease. 
These models serve as a useful tool to study the physiology 
of human hepatocytes in mammalian organisms (versus 
in vitro), and further advance drug development for liver 
therapy. Several genetically manipulated mice have been 
successfully used for this purpose. Thus, human hepatocytes, 
obtained from patients after liver transplantation or by liver 
biopsies, were transferred into immunodeficient transgenics 
Alb-uPA(tg(+/-)) that express uroplasminogen activa-
tor (uPA) under the transcriptional control of an albumin 
promoter.21,22 Another mouse model, Rag2-/-/Il2rg-/- mice 
(immunodeficient for recombinant activation gene-2 and 
the common γ-chain of the interleukin receptor mice), which 
are devoid of T and B cells, have been reported to be excel-
lent recipients of human hematopoietic xenografts.23 High 
efficiency of liver repopulation with human hepatocytes 
can be achieved when Rag2-/-/Il2rg-/- are crossed with 
Alb-uPA(tg(+/-)) mice.24 Finally, generation of mice triple 
mutant for Fah, Rag2 and Il2rg can be efficiently repopulated 
with human hepatocytes.25
The stem like properties of differentiating hepatocytes 
have encouraged development of protocols for hepatocyte 
transplantation in patients, a procedure which is an appeal-
ing alternative to auxiliary orthotropic liver transplantation. 
Hepatocyte transplantation has been used in attempts to treat 
genetic diseases, including familial hypercholesterolemia, 
Crigler–Najjar syndrome type I, glycogen storage disease 
type 1a, urea cycle defects and congenital deficiency of 
coagulation factor VII.26,27 So far, hepatocyte transplantation 
in humans has yielded only early but not sustained success 
rates. Problems such as appropriate number of donor hepato-
cytes for transplantation, rejection of transferred hepatocytes, 
localization of the engrafted cells, and hepatocyte activity 
are currently unresolved and require further investigation. 
Moreover, human adult liver cells are often not available 
in sufficient numbers for successful repopulation of the 
donor liver. Human hepatocytes are difficult to maintain in 
culture. They do not multiply long term in vitro and also do 
not tolerate cryopreservation well. Alternative resources for 
cell transplantation could be bipotential liver precursor cells, 
mesenchymal stem cells, embryonic stem cells (ESC), or 
inducible pluripotential cells (iPS), expanded and differenti-
ated in vitro into hepatocyte-like cells.
Liver precursor cells (oval cells)
Extensive or chronic liver damage, or prolonged intoxication 
and viral infection results in hepatocyte senescence, when 
mature hepatocyte proliferation is exhausted and suppressed.28,29 
In this case, liver regeneration is carried out by a heterogeneous 
population of progenitor cells, located within (or immediately 
adjacent to) the canal of Hering, which become activated and 
proliferate to replace the impaired hepatic parenchyma.4 These 
cells were first described by E Faber in 1956 as “small oval cells 
with scant lightly basophilic cytoplasm and pale blue-staining 
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nuclei” with a high nuclear/cytoplasmic ratio and an ovoid 
nucleus, and were called “oval cells”.6
Oval cells represent a bipotential precursor population, 
which can simultaneously co-express epithelial markers 
typical for cholangiocytes (CK-7, CK-19, and OV-6) and 
hepatocytes (alpha-fetoprotein and albumin), suggesting the 
close relationship of oval cells to differentiated liver paren-
chymal cells.30,31 Experiments tracing the transfer of 3H in 
thymidine-labeled oval cells confirm that these cells behave 
like bipotential progenitor cells and are able to differentiate 
into hepatocytes and cholangiocytes.30–34 Once activated and 
proliferating, it is proposed oval cells give rise to duct-like 
structures that arise from the periportal regions and spread 
into the liver acinus; several days after activation these duct-
like structures change appearance, and transform into clusters 
of small basophilic hepatocytes and mature bile ducts.
Several researchers have isolated and immortalized hepatic 
progenitors. Generation of these bipotential cell lines have 
helped in studying the molecular mechanisms that regulate 
and drive activation and differentiation of progenitor cells. In 
1998 Spagnoli and colleagues35 isolated and established the 
MMH (met murine hepatocyte) palmate cell line; immortal-
ized bipotential liver precursor cells derived from explants of 
embryonic liver of transgenic mice expressing a constitutively 
active truncated human Met receptor (cyto-Met) under control 
of the human α1-antitrypsin transcription unit.36 Under appro-
priate culture conditions, Palmate cells are able to differentiate 
into hepatocytes and cholangiocytes, and are widely used to 
dissect the molecular pathways of hepatocyte formation.37 To 
date, many inbred mouse strains have been used to isolate and 
manipulate bipotential liver cells38,39 that possess progenitor 
properties in vitro and are in vivo and able to differentiate into 
hepatocytes and colonize diseased livers in mice.35,38,40,41
Due to significant differences in the anatomical structure 
of murine and human canals of Hering, oval cells are named 
liver precursor cells (LPCs)9,42 in human livers. LPCs prolifer-
ate in chronic liver diseases, such as alcoholic disease, ste-
atohepatitis and viral hepatitis. However, LPCs are difficult 
to track and isolate because of the lack of a known definitive 
marker. Only recently, Schmelzer and colleagues43 have been 
able to isolate LPCs based on their expression of two surface 
markers, the epithelial cell adhesion molecule (EPCAM) 
and neural cell adhesion molecule (NCAM). LPCs have the 
ability to repopulate the liver in animal models.
According to our current understanding of liver regen-
eration, oval cells or LPCs represent a transient population 
of amplifying cells derived from normally quiescent true 
stem cells, which may reside in the biliary tree.8 In this 
context, the existence of a mesendodermal stem cell, with 
broader progenitor properties, capable of differentiation into 
hepatic parenchymal and non-parenchymal cells, has been 
hypothesized.7,44
Purification of hepatic progenitor cells is often based on 
cell sorting, using putative oval cell specific surface markers. 
However, identification of oval cells is difficult because the 
surface and intracellular markers expressed by human and rat 
oval cells significantly differ from those expressed by mouse 
oval cells. Thus, rat oval cells express OV6, bile duct epi-
thelium markers (CK-19) and hepatocyte markers (albumin, 
α-fetoprotein [AFP]) and resemble hepatoblasts.2 The detailed 
characterization of oval cells in the rat has been done by 
Yovchev and colleagues7 (Figure 2). Rat oval cells express 
markers described mostly for hepatopoietic stem cells, such as 
c-kit, Sca-1, CD34 and Thy-1.1.45–47 While this fact would sug-
gest that oval cells or true liver stem cells are replenished from 
BM progenitor cells, expression of Thy-1 by oval cells remains 
controversial.48–50 However, a recent study has demonstrated 
that Thy-1+ cells are located in rats in the “oval cell niche” 
and represent a subpopulation of activated mesenchymal-
epithelial cells that are distinct from resident stellate cells, 
myofibroblasts, or oval cells.51 Surprisingly, rat and mouse 
oval cells exhibit remarkable heterogeneity in expression of 
specific markers.52 In the search for specific precursor mark-
ers, it has been suggested that murine oval cells upregulate 
CK-19, AFP, albumin, Thy-1, CD34, delta-like protein (Dlk), 
EPCAM, TROP2, or the rat oval cell marker OV6.47,53–57 There 
is strong evidence independently demonstrated by several 
groups that mouse oval cells express CD133 and Sca-1.58–62 
However, in contrast to rat oval cells, mouse oval cells do not 
always express these markers, and until recently could be iden-
tified by expression of only one intracellular marker A6.47,57 
Hence, new antibodies against liver precursors may provide 
new markers of mouse oval cells (MIC1-1C3; OC2-1D11; 
OC2-2F3; OC2-1C6; OC2-2A6; OC2-6E10). Proliferating 
cells recognized by the new antibodies were located in ductal 
versus periductal areas, confirming the heterogenic nature of 
murine oval cell population63 and (Conigliaro and colleagues, 
unpublished observations) (Figure 2).
Many oval cell-specific markers are expressed intracellu-
larly and cannot be used for isolation of viable cells. Moreover, 
expression of many reported markers, especially in rats and 
humans, is not restricted to the hepatic precursor cells, and 
many proposed markers are also upregulated by other cell 
types. Although oval cells can be isolated using a combination 
of several surface proteins, their ability to exhibit precursor 
properties is further tested in vitro and/or in vivo. Since there 
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is no agreement in the literature as to which combination 
of markers defines oval cells, an epithelial colony-forming 
assay has been developed to assess the precursor properties 
of isolated cells. By culturing highly enriched precursors with 
one cell in each well of 96-well plates, the nature of each cell 
is analyzed. Isolated multipotent precursors have to undergo 
in vitro expansion prior to differentiation analysis or being 
reintroduced back into the mouse (via adoptive transfer into 
the spleen). In vitro expanded precursors are tested for their 
ability to form colonies. For example, precursors (CD133+ 
CK19+CK7+AFP+CD34+ and CD45-Ter119-c-kit-Thy-1-), 
isolated from adult livers of DDC-treated mice or untreated 
mice, exhibit distinct features of the multipotent population by 
forming two types of colonies in vitro, large mixed-lineage and 
small unilineage colonies.61 Hence, cells from DDC-treated 
mice form both mixed- and unilineage colonies, which can 
give rise to hepatocytes and cholangiocytes when transferred 
into FAH-/- mice, while the cells from untreated mice formed 
only unilineage colonies. In addition, clonal expansion of 
single cells from the large mixed-lineage colonies has dem-
onstrated that only 1% of the cells possessed true precursor 
properties.61
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Figure 2 Markers of oval cells.
Notes: intracellular and surface markers of oval cells in rats and mice differ from liver precursor cells (LPCs) in humans.  The most compelling markers that are potentially 
useful for isolation of oval cells in different species, are shown.
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Oval cells represent a heterogeneous population. Three 
different scenarios can explain the heterogeneity of oval cells 
and their place in the hierarchy of liver stem cells: 1) Oval 
cells are a pool of hepatic progenitors undergoing different 
stages of differentiation. 2) Originating from the liver stem 
cells, oval cells themselves can follow different pathways 
of differentiation and give rise to distinct classes of oval 
cells with highly specialized functions, whose bi-potential 
activity is carried out by the cholangiocyte or hepatocyte 
progenitors. 3) Alternatively, oval cells are heterogeneous 
hepatic precursor cells that may originate from common 
hepatobiliary stem cells during differentiation upon the needs 
of hepatic tissue.9
Liver stem cells
Several reports have described the isolation of pluripotent 
cells from human fetal (human fetal liver multipotent pre-
cursor cell, [HFLMPC])64 and adult livers.65 HFLMPCs 
are classified as mesenchymal-epithelial transitional cells, 
which can be maintained in long-term culture in an undif-
ferentiated state, but when properly treated differentiate into 
hepatocytes and cholangiocytes as well as into cells of several 
mesenchymal lineages (fat, cartilage, bone and endothelial 
cells). Human liver stem cells (HLSCs) are proposed to be a 
mesenchymal liver population with a partial commitment to 
hepatic cells. When cultured in the appropriate differentiation 
media, HLSCs can be induced to differentiate into mature 
hepatocytes, osteoblasts, or endothelial cells, showing a 
multilineage potentiality. Adult liver precursor cells appear 
in vivo in response to several types of pathological liver 
injury, especially when hepatocyte replication is impaired. 
These cells are histologically identified by the expression 
of cholangiocyte markers and proliferate in the portal area 
of the hepatic lobule. HLSCs may play an important role in 
liver regeneration by providing the self-renewing ability of 
bipotent primitive hepatic cells.61
The success rate of using the stem cells for restoring tis-
sues depends on the ability to expand these cells in vitro and, 
in many cases, to direct their differentiation towards a specific 
cell lineage.66–69 Although in vitro expansion, growth and dif-
ferentiation of isolated fetal stem cells does not necessarily 
drive their differentiation in vivo, it provides a unique system 
to study stem cell regulation, and to optimize conditions to 
direct endogenous regenerative potential towards a lineage-
specific differentiation. In this regard, RLSCs (resident liver 
stem cells), a non- tumorigenic stable stem cell line obtained 
from fetal and neonatal murine livers, represent a useful tool 
to study stem cell biology.70 In their undifferentiated state, 
RLSCs maintain a stem cell transcriptional profile and ability 
for self-renewal. Undifferentiated RLSCs co-express mesen-
chymal (eg, calponin 1), endodermal (eg, FoxA1 and aFP) and 
neuroectodermal (eg, nestin) stem cell markers together with 
several “stem” related genes (chromatin remodeling genes) 
crucial for the activation of stem cell genetic program. RLSCs 
differentiate into hepatocytes and cholangiocytes in vivo and 
in vitro and, when cultured under appropriate conditions, can 
give rise to mesenchymal and neuro-ectodermal cell lineages, 
such as osteoblasts/osteocytes, chondrocytes, astrocytes and 
neuronal cells. The ability to spontaneously differentiate into 
hepatocytes and the lack of albumin expression in an undif-
ferentiated state, places RLSCs at the pre-hepatoblast/liver 
precursor cell hierarchy of liver stem cells. RLSCs were 
used71 to study liver zonation, demonstrating for the first 
time a direct convergence of the canonical Wnt signaling on 
the HNF4α driven transcription in RLSC derived periportal 
hepatocytes.
BM contribution to liver regeneration
Significant contribution of the BM to hepatocyte regeneration 
was originally established in the FAH-/- mice, which develop 
liver failure in response to withdrawal of NTBC from their 
drinking water. Transplantation of total BM or myeloid cells 
into these mice results in fusion with the recipient hepatocytes, 
their clonal expansion, and reconstitution of normal liver 
mass. Despite this extraordinary ability of myeloid cells to 
rescue the phenotype of FAH-/- hepatocytes, such phenom-
enon was not (or very rarely) observed in response to other 
types of liver injury (CCl
4
, bile duct ligation [BDL]), sug-
gesting that hematopoietic cells have a limited contribution 
to hepatocyte population under physiological conditions or in 
response to injury.72,73 Meanwhile, there is some evidence that 
hematopoietic stem cells can contribute to replenishment of 
liver precursors or stem cells, since transplantation of highly 
purified hematopoietic stem cells resulted in generation of 
BM-derived ductular cells and hepatocytes.10,74,75 One can 
speculate that BM cells can replace oval cells or liver stem 
cells. In a recent study, Cho and colleagues have investigated 
the ability of purified hematopoietic stem cells (HSCs), mes-
enchymal stem cells (MSCs) and mononuclear cells to engraft 
and contribute to liver regeneration in response to injury. Of 
these populations, the MSCs transplanted group showed the 
highest engraftment rate and exhibited the utmost potential to 
differentiate into hepatocytes when co-cultured with injured 
liver cells.76
MSCs have been isolated from several sources, BM, 
cord blood, amniotic fluid, placenta and adipose tissue, and 
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therefore, become a prime candidate for cell therapy. Several 
studies have demonstrated that MSCs isolated and expanded 
in vitro can be induced to differentiate into hepatocyte-like 
cells.77,78 However, only a low level of liver repopulation 
with the MSCs, derived from umbilical cord or adipose 
tissues, has been reported. In addition, differentiation of 
MSCs into hepatocytes requires both in vitro expansion and 
treatment with hepatogenic factor prior to transplantation. 
Several attempts have been made to treat liver pathologies 
with undifferentiated MSCs. Thus, human umbilical cord 
blood-derived cells transplanted into non-obese diabetic-
severe combined immunodeficient (NOD-SCID) mice 
generated clusters of donor-derived hepatocytes in response 
to CCl
4
.79 Although transplantation of MSCs often results in 
attenuation or improvement of liver disease, current studies 
have not provided a definitive proof for MSC differentia-
tion into functional hepatocytes in vivo.14,77,79–81 Even more 
controversial is the role of MSCs in fibrosis. In response 
to fibrogenic liver injury (CCl
4
, BDL), both hematopoietic 
and MSCs have shown limited contribution to hepatocyte 
replenishment, but in turn, actively differentiated into 
fibrogenic cells.72,73,82 Moreover, Russo and colleagues have 
reported that MSCs directly differentiate into myofibroblasts 
in the damaged liver and facilitate fibrogenic processes.83 
Therefore, it remains unclear if infusion of MSC fulfills 
the function or increases the risk from the transplantation 
therapy.
Conclusion
This review has summarized the potential contribution of 
intrahepatic and BM cells to liver regeneration. There are 
at least three sources of intrahepatic cells that are capable 
of differentiating into hepatocytes and cholangiocytes. 
In response to injury, hepatocytes themselves undergo 
activation, proliferate and differentiate into parenchy-
mal cells. This process is the best documented and most 
understood, and currently provides the most therapeutic 
potential. Meanwhile, oval cells, heterogeneous liver 
precursor cells that most likely arise from the biliary 
tree, may contribute to newly formed hepatocytes and 
cholangiocytes. However, very little is known about the 
biology of oval cells, especially the conditions suitable to 
manipulate oval cell differentiation and expansion in vitro 
prior to reintroduction in vivo. Even less is known about 
“true” liver stem cells and their regenerative potential. 
Future studies are likely to further characterize intrahe-
patic stem cells, and new findings are needed to improve 
cell transplantation therapy.
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